Turning Point Therapeutics Provides Regulatory Updates

NEXT STORY
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
PREV STORY
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Somatrogon Phase 3 Pediatric Trial Results will be presented on June 8 at ENDO Online 2020

author_avatar
NASDAQ Market News

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

WALTHAM, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (“Syndax” or the “Company”) ...

author_avatar
NASDAQ Market News

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

ALPHARETTA, Ga., June 13, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical ...

author_avatar
NASDAQ Market News